Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers
- 1 November 2011
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 123 (2) , 196-199
Abstract
No abstract availableKeywords
Funding Information
- NIH (P01-CA52477-17)
This publication has 23 references indexed in Scilit:
- A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)Gynecologic Oncology, 2011
- Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivityAnnals of Oncology, 2010
- Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor TopotecanCancer Research, 2010
- Resistance to therapy caused by intragenic deletion in BRCA2Nature, 2008
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersNature, 2008
- Topoisomerase I inhibitors: camptothecins and beyondNature Reviews Cancer, 2006
- BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma casesCancer, 2005
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Prevalence and Penetrance of Germline BRCA1 and BRCA2 Mutations in a Population Series of 649 Women with Ovarian CancerThe American Journal of Human Genetics, 2001
- Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer FamiliesThe American Journal of Human Genetics, 1998